125 related articles for article (PubMed ID: 6882879)
21. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
Aitio ML
Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
[TBL] [Abstract][Full Text] [Related]
22. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
Karim A; Kook C; Novotney RL; Zagarella J; Campion J
Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
[TBL] [Abstract][Full Text] [Related]
24. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
Hasselström J; Enquist M; Hermansson J; Dahlqvist R
Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
[TBL] [Abstract][Full Text] [Related]
25. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.
Karim A; Kook C; Campion J; Doherty M
Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
Shaw LM; Doherty JU; Waxman HL; Josephson ME
Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
[TBL] [Abstract][Full Text] [Related]
27. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
[TBL] [Abstract][Full Text] [Related]
28. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
[TBL] [Abstract][Full Text] [Related]
29. The absorption of disopyramide in animals determined using a stable isotope co-administration technique.
Haskins NJ; Waddell KA; Ford GC; Spalton PN; Walls CM; Forrest TJ; Palmer RF
Biomed Mass Spectrom; 1980 Feb; 7(2):80-3. PubMed ID: 7407335
[TBL] [Abstract][Full Text] [Related]
30. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
31. Disposition kinetics of disopyramide in patients with renal insufficiency.
Shen DD; Cunningham JL; Shudo I; Azarnoff DL
Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetics of disopyramide.
Karim A; Nissen C; Azarnoff DL
J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
[No Abstract] [Full Text] [Related]
34. Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?
Aitio ML; Vuorenmaa T
Br J Clin Pharmacol; 1980 Feb; 9(2):149-52. PubMed ID: 7356902
[TBL] [Abstract][Full Text] [Related]
35. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
Upton RA; Williams RL
J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
[TBL] [Abstract][Full Text] [Related]
36. Effect of altered disopyramide binding on its pharmacologic response in rabbits.
Huang JD; Oie S
J Pharmacol Exp Ther; 1982 Nov; 223(2):469-71. PubMed ID: 7131300
[TBL] [Abstract][Full Text] [Related]
37. The stereoselective disposition of disopyramide in the dog.
Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
[TBL] [Abstract][Full Text] [Related]
38. The effect of enzyme induction on the metabolism of disopyramide in man.
Aitio ML; Mansury L; Tala E; Haataja M; Aitio A
Br J Clin Pharmacol; 1981 Mar; 11(3):279-85. PubMed ID: 7213529
[TBL] [Abstract][Full Text] [Related]
39. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
[TBL] [Abstract][Full Text] [Related]
40. The influence of blood collection technique on serum and plasma protein binding of disopyramide.
Haughey DB; Lima JJ
Eur J Clin Pharmacol; 1982; 22(2):185-9. PubMed ID: 7094989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
